The relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention
Yazarlar (9)
Doç. Dr. Timor Omar Kafkas Üniversitesi, Türkiye
Prof. Dr. Yavuz KARABAĞ Kafkas Üniversitesi, Türkiye
Prof. Dr. Metin ÖĞÜN Kafkas Üniversitesi, Türkiye
Doç. Dr. İnanç ARTAÇ Kafkas Üniversitesi, Türkiye
Dr. Öğr. Üyesi Muammer KARAKAYALI Kafkas Üniversitesi, Türkiye
Doç. Dr. Doğan İLİŞ Kafkas Üniversitesi, Türkiye
Doç. Dr. Ayça ARSLAN Kafkas Üniversitesi, Türkiye
Cihan Dündar Türkiye
Prof. Dr. İbrahim RENCÜZOĞULLARI Kafkas Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(Ulusal alan endekslerinde (TR Dizin, ULAKBİM) yayınlanan tam makale)
|
||
| Dergi Adı | Journal of Health Sciences and Medicine | ||
| Dergi ISSN | 2636-8579 | ||
| Dergi Tarandığı Indeksler | TR DİZİN | ||
| Makale Dili | Türkçe | Basım Tarihi | 03-2024 |
| Cilt / Sayı / Sayfa | 7 / 2 / 199–205 | DOI | 10.32322/jhsm.1413552 |
| Makale Linki | http://dx.doi.org/10.32322/jhsm.1413552 | ||
| UAK Araştırma Alanları |
Kardiyoloji
|
||
| Özet |
| Aims The current study aimed to investigate the relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention (pPCI). Methods Patients with ST-elevation myocardial infarctions (STEMI) who underwent pPCI in our center between May 01, 2022, and 20 August 2023 were included in this cross-sectional observational study. Patients were classified into two groups according to the occurrence of no-reflow during pPCI. Findings were compared between the two groups. Results A total of 332 patients [male, 75 (%82.8)] with STEMI undergoing pPCI, were included. Among them, 35 (10.5%) patients developed no-reflow. Homocysteine level was significantly higher in the no-reflow(+) group than the no-reflow(-) group [median (IQR), 19.02 (16.11-22.23 vs. 12.45 (10.99-14.93), p=0.019]. According to the multivariate analysis, homocysteine level, TIMI risk score, and postdilatation were independent predictors of no-reflow occurrence [Odds Ratio (95% CI), 1.127 (1.042-1.218), p=0.003, 1.385 (1.157-1.659), p<0.001, and 2.396 (1.092-5.257), p=0.029, respectively]. Considering the ROC curve analysis for homocysteine predicting no-reflow, the area under the curve (AUC) was 0.714 with an optimal cut-off value of 14.1 (sensitivity of 71%, specificity 62%). Conclusion Higher admission homocysteine levels were associated with no-reflow development in STEMI patients during pPCI. Higher levels of homocysteine may identify a subset of patients at a higher risk of no-reflow development during pPCI. |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 3 |